Posts

Showing posts with the label cancer drugs

Cancer Diary: The Double-Edge Sword of Good and Harm from Cancer Treatments

Image
A new study from the Memorial Sloan Kettering Cancer Center has revealed a major side effect of the oral medication alpelisib that is prescribed to  breast cancer patients . Read about what the findings were HERE . Sheesh! It is so disappointing -- and frustrating -- to have to deal with the side-effects of the only drugs that can save your life. We went through that a little with Carl's Cancer of Uknown Primary. He did not last long enough to have many side effects. But many, many people do! Fingers crossed for new drugs that are free of bad side effects. For other Cancer Diary posts, click  HERE . Blog editor's note: As a memorial to Carl, and simply because it is truly needed, MSI Press is now hosting a web page,  Carl's Cancer Compendium , as a one-stop starting point for all things cancer, to make it easier for those with cancer to find answers to questions that can otherwise take hours to track down on the Internet and/or from professionals. The CCC is expanded and up

Cancer Diary: Cancer Drugs

Image
  Today's post is short -- just a link -- but it could be more important than much longer posts. I recently came across the National Comprehensive Cancer Network and its compendium of drugs. Like Carl's Cancer Compendium, this collection of searchable and readily available information is a goldmine that I wish I had had when Carl was dying from cancer. You can check out this rich complication of cancer drugs and information about them HERE .  See other posts on cancer drugs . See other   Cancer Diary   posts. Blog editor's note: As a memorial to  Carl Don Leaver , co-founder of MSI Press LLC, and simply because it is truly needed, MSI Press is now hosting a web page,  Carl's Cancer Compendium , as a one-stop starting point for all things cancer, to make it easier for those with cancer to find answers to questions that can otherwise take hours to track down on the Internet and/or from professionals. The web page is in its infancy but expected to expand into robustness.